TD Cowen Cuts Medline (NASDAQ:MDLN) Price Target to $45.00

by · The Markets Daily

Medline (NASDAQ:MDLN – Free Report) had its target price lowered by TD Cowen from $53.00 to $45.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

MDLN has been the subject of a number of other research reports. Truist Financial reduced their price target on Medline from $56.00 to $47.00 and set a “buy” rating for the company in a report on Thursday, August 6th. William Blair reissued an “outperform” rating on shares of Medline in a report on Thursday, June 4th. Barclays cut their price objective on Medline from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Monday, June 1st. Citigroup reduced their target price on Medline from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Tigress Financial increased their target price on Medline from $60.00 to $62.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.42.

View Our Latest Report on Medline

Medline Stock Up 1.3%

MDLN stock opened at $35.50 on Monday. Medline has a one year low of $32.81 and a one year high of $50.88. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.61 and a current ratio of 4.33. The firm’s fifty day moving average is $38.23 and its 200 day moving average is $41.50. The firm has a market cap of $46.64 billion and a PE ratio of 110.94.

Medline (NASDAQ:MDLN – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.18. The firm had revenue of $7.68 billion during the quarter. On average, research analysts forecast that Medline will post 1.49 EPS for the current year.

Insider Transactions at Medline

In other Medline news, major shareholder Private Ltd Gic sold 1,976,618 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $35.60, for a total value of $70,367,600.80. Following the transaction, the insider directly owned 25,264,760 shares in the company, valued at $899,425,456. The trade was a 7.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jessi L. Corcoran acquired 5,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was acquired at an average price of $34.15 per share, with a total value of $170,750.00. Following the completion of the transaction, the insider directly owned 5,000 shares of the company’s stock, valued at $170,750. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold a total of 2,938,896 shares of company stock worth $104,656,454 in the last ninety days. Insiders own 0.81% of the company’s stock.

Institutional Trading of Medline

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MDLN. Bank of New York Mellon Corp purchased a new stake in Medline during the 2nd quarter worth approximately $40,430,000. E. Ohman J or Asset Management AB acquired a new stake in Medline during the 2nd quarter worth approximately $508,000. GAMMA Investing LLC boosted its position in Medline by 68.3% in the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after buying an additional 254 shares during the period. Parallel Advisors LLC grew its stake in shares of Medline by 1,073.3% in the first quarter. Parallel Advisors LLC now owns 5,280 shares of the company’s stock worth $235,000 after acquiring an additional 4,830 shares in the last quarter. Finally, CTC Alternative Strategies Ltd. acquired a new position in shares of Medline in the first quarter worth $1,048,000.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

  • Positive Sentiment: JPMorgan lowered its price target from $53 to $46 but maintained an Overweight rating, implying substantial upside from recent trading levels. JPMorgan Medline price target
  • Positive Sentiment: TD Cowen reduced its target to $45 while retaining a Buy rating, citing Medline’s cash flow and longer-term growth prospects. Tigress Financial also kept a Buy rating despite cutting its target from $62 to $55. TD Cowen Medline price target Tigress Financial analyst action
  • Positive Sentiment: Medline’s latest quarterly results exceeded expectations, with earnings per share of $0.50 versus the $0.32 consensus estimate and revenue of approximately $7.7 billion. The earnings beat provides fundamental support for the stock, although its elevated valuation remains a consideration.
  • Neutral Sentiment: Analyst sentiment remains broadly favorable, with a consensus rating of Moderate Buy and an average price target of $47.69. However, the range of recent target cuts indicates that estimates are being recalibrated.
  • Negative Sentiment: Wells Fargo cut its price target from $45 to $34 and assigned an Equal Weight rating. The target is slightly below recent levels, signaling limited near-term upside from that firm’s perspective. Wells Fargo Medline price target
  • Negative Sentiment: Major shareholder Private Ltd Gic sold 590,284 shares for approximately $21 million, reducing its stake by 2.36%. The investor also reported additional sales earlier in the week, which could weigh on sentiment despite its remaining sizable ownership. Medline shareholder sale
  • Negative Sentiment: Kaplan Fox and Kessler Topaz Meltzer & Check announced investigations into potential federal securities-law violations involving Medline. The announcements do not establish wrongdoing, but they add legal, reputational and headline risk for investors. Kaplan Fox Medline investigation Kessler Topaz Medline investigation

About Medline

(Get Free Report)

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

Featured Articles